Form 4: Galectin Therapeutics CMO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Galectin Therapeutics' Chief Medical Officer, Khurram Jamil, executed pre-planned sales of common stock on November 13, 2025, following option exercises.
Summary
- Khurram Jamil, Chief Medical Officer of Galectin Therapeutics Inc. (GALT), conducted multiple transactions on November 13, 2025, under a Rule 10b5-1 trading plan adopted on July 15, 2025.
- Jamil exercised stock options to acquire a total of 99,250 shares of common stock, consisting of 41,500 shares at an exercise price of $2.20, 41,500 shares at $2.50, and 16,250 shares at $1.23.
- Concurrently, Jamil sold a total of 99,250 shares of common stock at a weighted average price of $5.47 per share, with individual sales prices ranging from $5.41 to $5.89.
- Following these transactions, Jamil directly beneficially owns 4,479 shares of common stock.
- Remaining derivative holdings include 108,500 stock options exercisable at $2.20, 58,500 stock options exercisable at $2.50, and 48,750 stock options exercisable at $1.23.
Sentiment
Score: 5
Explanation: The filing reports routine insider transactions (option exercises and sales) executed under a pre-arranged 10b5-1 trading plan. This is generally considered a neutral event as it reflects personal financial planning rather than a discretionary statement about the company's prospects.
Positives
- The insider's option exercises were at significantly lower prices ($1.23, $2.20, $2.50) compared to the sale price ($5.47 weighted average), indicating a profitable transaction for the reporting person.
- The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, suggesting the sales were not based on new, non-public information.
Negatives
- Insider selling, even when pre-planned, can sometimes be perceived negatively by the market, especially if the volume is significant relative to the insider's total holdings.
Future Outlook
N/A
Industry Context
N/A
Stakeholder Impact
- Shareholders may observe a slight increase in the float due to option exercises, but the overall impact is minimal given the pre-planned nature of the sales.
Key Dates
| Date | Description |
|---|---|
| 2024-10-31 | Vesting date for 25,000 stock options (part of the $2.50 strike price options). |
| 2025-01-31 | Vesting date for 25,000 stock options (part of the $2.50 strike price options). |
| 2025-03-11 | Vesting date for 50,000 stock options (part of the $2.20 strike price options). |
| 2025-03-31 | Date 41,500 stock options (exercisable at $2.20) became exercisable for the reported transaction. |
| 2025-04-30 | Vesting date for 25,000 stock options (part of the $2.50 strike price options). |
| 2025-06-30 | Date 16,250 stock options (exercisable at $1.23) became exercisable for the reported transaction, and vesting date for 16,250 stock options (part of the $1.23 strike price options). |
| 2025-07-15 | Date the Rule 10b5-1 plan was adopted by the reporting person. |
| 2025-07-31 | Date 41,500 stock options (exercisable at $2.50) became exercisable for the reported transaction, and vesting date for 25,000 stock options (part of the $2.50 strike price options). |
| 2025-11-13 | Date of reported transactions (option exercises and stock sales). |
| 2025-11-14 | Date the Form 4 was filed and date the Issuer's Quarterly Report on Form 10-Q, disclosing the 10b5-1 plan, was filed with the SEC. |
| 2025-12-31 | Vesting date for 16,250 stock options (part of the $1.23 strike price options). |
| 2026-03-11 | Scheduled vesting date for 50,000 stock options (part of the $2.20 strike price options). |
| 2026-06-30 | Scheduled vesting date for 16,250 stock options (part of the $1.23 strike price options). |
| 2026-12-31 | Scheduled vesting date for 16,250 stock options (part of the $1.23 strike price options). |
| 2027-03-11 | Scheduled vesting date for 50,000 stock options (part of the $2.20 strike price options). |
| 2034-03-20 | Expiration date for stock options exercisable at $2.20. |
| 2034-08-01 | Expiration date for stock options exercisable at $2.50. |
| 2035-01-23 | Expiration date for stock options exercisable at $1.23. |
Recommendation
holdThe filing details pre-scheduled insider sales under a 10b5-1 plan, which are typically for personal financial management and do not inherently signal a change in the company's fundamental outlook. While insider selling can sometimes be a negative signal, the pre-planned nature mitigates this concern. Without additional information on the company's performance or strategic direction, a 'hold' recommendation is appropriate as this filing alone does not provide a strong basis for a 'buy' or 'sell' decision.
Keywords
Galectin Therapeutics, GALT, Khurram Jamil, Insider Trading, Form 4, Stock Options, Share Sale, 10b5-1 Plan, Chief Medical Officer, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.